Recruiting Macular Degeneration Studies in Pasadena
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)...
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies....
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W)....
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD....
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular dege...
About Macular Degeneration Clinical Trials in Pasadena
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 5 macular degeneration clinical trials recruiting participants in Pasadena, CALIFORNIA. These studies are seeking a combined 1,494 participants. Research is being sponsored by Kodiak Sciences Inc, Janssen Research & Development, LLC, Genentech, Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in Pasadena — FAQ
Are there macular degeneration clinical trials in Pasadena?
Yes, there are 5 macular degeneration clinical trials currently recruiting in Pasadena, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Pasadena?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pasadena research site will contact you about next steps.
Are clinical trials in Pasadena free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pasadena studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 5 active trials in Pasadena are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov